Future antibody avenues for cutaneous lymphoma treatment

Speaking from the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, Pietro Quaglino, MD, of the University of Turin, Turin, Italy, gives his insight into the novel therapies being explored for cutaneous T-cell lymphomas, including bretuximab vedotin and mogamulizumab .

• Kategorya